<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: Cadherin 1 gene (&lt;i&gt;CDH1&lt;/i&gt;)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: Cadherin 1 gene (<i>CDH1</i>)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: Cadherin 1 gene (<i>CDH1</i>)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy L Davis, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1206991532"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> CDH1 </em>gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2986346162"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H802584853"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>).</p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the genotype</strong> – Identifies variants. Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, or comparable accreditation body in other jurisdictions, if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected hereditary diffuse gastric cancer [HDGC] syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. May require updating, especially for variants of uncertain significance (VUS). </p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H625675437"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>Pathogenic variants in <em>CDH1</em> can lead to a number of cancers and congenital abnormalities, collectively referred to as HDGC syndrome, an autosomal dominant disorder. Lobular breast cancer and nonsyndromic cleft lip/palate are also part of the HDGC syndrome. The term hereditary lobular breast cancer (HLBC) has been proposed as the presence of a pathogenic germline <em>CDH1</em> variant in either an isolated individual with LBC, or a family with one or more LBC cases in first-degree or second-degree relatives, but no known DGC in either situation.</p><p>The <em>CDH1 </em>gene encodes E-cadherin, a protein on the cell surface that promotes cell-cell adhesion. <em>CDH1</em> is a tumor suppressor gene, and therefore a somatic second hit is required in addition to the germline pathogenic variant for initiation of tumor formation. The trigger and molecular mechanisms by which the second allele of <em>CDH1</em> is inactivated appear to be diverse, and include promoter hypermethylation, mutation, and loss of heterozygosity. The end result is biallelic inactivation and loss of expression of E-cadherin. Of note, another gene associated with HDGC is <em>CTNNA1</em>.</p><p class="headingAnchor" id="H4222142397"><span class="h3">Gastric cancer</span><span class="headingEndMark"> — </span>HDGC is an inherited form of diffuse-type gastric cancer, a highly invasive tumor that is characterized by young age at diagnosis, late stage at presentation, and a poor prognosis. The lifetime risk of gastric cancer in individuals from affected families is variable, and likely high for families that meet traditional testing criteria for HDGC (cumulative risk of gastric cancer by age 80 years is as high as 70 percent for men and 56 percent for women). More contemporary estimates of the cumulative risk of gastric cancer in carriers of a pathogenic or likely pathogenic variant by age 80 years are 37 to 42 percent for men, and 25 to 33 percent for women [<a href="#rid2">2,3</a>]. These estimates are derived from <em>CDH1</em> pathogenic and likely pathogenic variant-positive kindreds identified through commercial testing for hereditary cancer risk using multigene panel testing that is unselected for HDGC clinical criteria. Affected patients may develop DGC in their teens or early 20s [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Risk of cancer in carriers of a pathogenic or likely pathogenic CDH1 variant'</a>.) </p><p class="headingAnchor" id="H1423068799"><span class="h3">Breast cancer</span><span class="headingEndMark"> — </span>Individuals with HDGC syndrome have an increased risk for invasive lobular breast cancer (ILBC), an estrogen and progesterone receptor (ER and PR) positive breast cancer type that is challenging to diagnose because these tumors often do not form a discrete mass nor do they have a classical malignant appearance on mammography. These breast cancers generally have a good prognosis. The cumulative risk by age 80 is approximately 42 to 55 percent [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'CDH1 (Hereditary diffuse gastric cancer syndrome)'</a> and  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Breast cancer'</a>.)</p><p class="headingAnchor" id="H2856291243"><span class="h3">Nonsyndromic cleft lip/palate</span><span class="headingEndMark"> — </span>There are reports of an association between cleft lip/palate and <em>CDH1</em> pathogenic or likely pathogenic variants in families with HDGC.</p><p class="headingAnchor" id="H3076840504"><span class="h3">Blepharocheilodontic syndrome</span><span class="headingEndMark"> — </span>Blepharocheilodontic syndrome is characterized by lower eyelid ectropion, upper eyelid distichiasis, euryblepharon, bilateral cleft lip and palate, and conical teeth. Rarely, patients may have imperforate anus.</p><p class="headingAnchor" id="H212781906"><span class="h3">Other associations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colon cancer </strong>– Although cases of colorectal and appendiceal signet ring cell carcinomas have been reported in carriers of a <em>CDH1</em> pathogenic or likely pathogenic variant, there is no evidence for a significantly increased risk of colorectal cancer or other cancer types in such individuals [<a href="#rid6">6,7</a>]. </p><p></p><p class="headingAnchor" id="H2671744387"><span class="h1">IMPLICATIONS OF A PATHOGENIC OR LIKELY PATHOGENIC VARIANT</span><span class="headingEndMark"> — </span>We consider all individuals with a pathogenic or likely pathogenic variant in <em>CDH1 </em>to be at risk for hereditary diffuse gastric cancer (HDGC) syndrome, regardless of the initial reason for testing. </p><p>Discussion should include the range of associated risks, possible interventions for cancer surveillance or risk reduction, and implications for family members. (See <a class="local">'At-risk relatives'</a> below and  <a class="medical medical_review" href="/z/d/html/133261.html" rel="external">"Gene test interpretation: <i>CTNNA1</i>", section on 'At-risk relatives'</a>.)</p><p>Counseling may require additional visits or referrals. Acting upon genetic testing results is rarely an emergency; the individual can be reassured that management decisions can be deferred until questions are answered.</p><p>We adhere to guidelines by the International Gastric Cancer Linkage Consortium (IGCLC) for cancer surveillance and risk reduction [<a href="#rid8">8</a>]. Findings in family members (type of cancers, age of onset) may also inform surveillance (for example, starting at an earlier age if a family member has an earlier age of onset). </p><p>Several evaluations and interventions are recommended to reduce the risk of cancers associated with HDGC syndrome  (<a class="graphic graphic_algorithm graphicRef132014" href="/z/d/graphic/132014.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric cancer</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risk-reducing (prophylactic) total gastrectomy is recommended in individuals with a germline <em>CDH1</em> pathogenic or likely pathogenic variant from families with confirmed HDGC syndrome. Prophylactic gastrectomy is generally advised as early as age 20 years or at an age of five years younger than the youngest family member who developed gastric cancer, whichever is earlier. However, the timing of the operation may vary according to the preferences, age, and physical as well as psychological well-being of the individual. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with a <em>CDH1</em> pathogenic or likely pathogenic variant with no significant personal or family history of cancer associated with HDGC syndrome should be referred to specialist centers for consultation about screening and preventive surgery. The magnitude of the cancer risk for patients with <em>CDH1</em> variants who lack a family history of multiple gastric cancers remains uncertain. At the very least, any individual identified with a <em>CDH1</em> pathogenic variant who chooses to defer total prophylactic gastrectomy should follow the endoscopy screening protocol. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper endoscopy with biopsies (Cambridge protocol) to screen for gastric cancer may be considered in selected patients. Potential candidates for upper endoscopy include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals with a pathogenic or likely pathogenic variant who are identified prior to age 20 years may undergo annual surveillance endoscopy with surgery deferred until after age 20.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients over age 20 years who receive a recommendation for prophylactic gastrectomy, but who decide to postpone (or refuse) the procedure. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who chose to undergo upper endoscopy to screen for gastric cancer should be informed that there is no reliable endoscopic screening test for the early diagnosis of diffuse gastric cancer. Gastric cancers that arise in patients with HDGC are signet ring cancers that are located beneath an intact surface epithelium and only become visible on direct mucosal evaluation later in the disease process. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who carry a pathologic <em>CDH1</em> mutation who refuse or delay prophylactic gastrectomy should be screened for infection with <em>Helicobacter pylori </em>(<em>H. pylori</em>) and treated if positive.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total gastrectomy is indicated in patients with signet ring cell carcinoma on gastric biopsy. Patients with a positive biopsy finding (signet ring cell carcinoma) who still wish to forego total gastrectomy should have endoscopy repeated at six-month intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> –<strong> </strong>Women are managed similarly to other high-risk breast cancer conditions with annual breast magnetic resonance imaging (MRI; this test can be combined with mammography) starting at age 30. The option of risk-reducing mastectomy should be discussed. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'CDH1 (Hereditary diffuse gastric cancer syndrome)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional details and supporting evidence are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer"</a> and  <a class="medical medical_review" href="/z/d/html/8041.html" rel="external">"Surgical management of hereditary diffuse gastric cancer"</a> and  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H755252929"><span class="h1">IMPLICATIONS OF A NEGATIVE TEST</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic variants were identified  (<a class="graphic graphic_algorithm graphicRef132014" href="/z/d/graphic/132014.html" rel="external">algorithm 1</a>). However, some tests only evaluate a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive) or in other genes (eg, alpha-1-catenin [<em>CTNNA1</em>] gene).</p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>CDH1</em> variant is known and the tested individual does not have that variant, usually they can be reassured that they are not at high risk for hereditary diffuse gastric cancer (HDGC) syndrome, with caveats outlined above (see <a class="local">'How to read the report'</a> above and  <a class="medical medical_review" href="/z/d/html/133261.html" rel="external">"Gene test interpretation: <i>CTNNA1</i>", section on 'How to read the report'</a>). However, it is important to provide an individualized risk assessment based on family history and other risk factors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>CDH1 </em>variant is not known and results of genetic testing are negative, the extent of additional testing depends on the personal and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to guide additional genetic testing based on the personal and family history. Intensive endoscopic screening may be considered in patients who meet HDGC criteria. (See <a class="local">'Locating an expert'</a> below and  <a class="medical medical_review" href="/z/d/html/133261.html" rel="external">"Gene test interpretation: <i>CTNNA1</i>", section on 'Locating an expert'</a>.)</p><p></p><p class="headingAnchor" id="H211078711"><span class="h1">IMPLICATIONS OF A VUS</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history. Annual endoscopic surveillance for gastric cancer is suggested in patients with a <em>CDH1</em> VUS for at least two years; it should ideally be done as a part of a research study [<a href="#rid8">8</a>]. Women with a <em>CDH1</em> VUS should receive individualized breast cancer risk assessment and surveillance recommendations  (<a class="graphic graphic_algorithm graphicRef132014" href="/z/d/graphic/132014.html" rel="external">algorithm 1</a>).</p><p>New information may become available; the testing laboratory or other resources should be consulted periodically for updates (eg, annually). (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer", section on 'Surveillance for breast cancer'</a>.)</p><p>The implications of genetic test results should be discussed with the individual's oncologist or surgeon; in some cases, referral to a specialist in hereditary cancer syndromes may be appropriate. </p><p class="headingAnchor" id="H1704591142"><span class="h1">CONSIDERATIONS FOR FAMILY MEMBERS</span></p><p class="headingAnchor" id="H3534977207"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Reproductive counseling is appropriate for individuals with a pathogenic or likely pathogenic <em>CDH1</em> variant who are considering childbearing.</p><p>Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H3732328950"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant or likely pathogenic variant in <em>CDH1 </em>should inform their at-risk relatives about the importance of genetic counseling and possible testing. </p><p class="bulletIndent1"><span class="glyph">●</span>The risk of having inherited the variant is 50 percent for first-degree relatives, including siblings and parents; if one parent carries the variant, then the risk to siblings is also 50 percent. Others at risk may include aunts, uncles, nieces, nephews, and cousins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually, the variant segregates on the side of the family with a history of gastric or breast cancer; however, if possible, it is recommended to test a parent or other relative with cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing for at-risk relatives may be considered as early as 16 to 18 years. Age of cancer onset for relatives may help guide the timing. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a> and <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above and  <a class="medical medical_review" href="/z/d/html/133261.html" rel="external">"Gene test interpretation: <i>CTNNA1</i>", section on 'Implications of a pathogenic or likely pathogenic variant'</a>.)</p><p></p><p class="headingAnchor" id="H4147832334"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H259182773"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary diffuse gastric cancer (HDGC) syndrome – (See  <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">"Hereditary diffuse gastric cancer"</a> and  <a class="medical medical_review" href="/z/d/html/8041.html" rel="external">"Surgical management of hereditary diffuse gastric cancer"</a> and  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes", section on 'CDH1 (Hereditary diffuse gastric cancer syndrome)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cleft lip/palate – (See  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate"</a> and  <a class="medical medical_review" href="/z/d/html/6302.html" rel="external">"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx"</a> and  <a class="medical medical_review" href="/z/d/html/2920.html" rel="external">"Overview of craniofacial clefts and holoprosencephaly"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H2633977226"><span class="h2">Locating an expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=130654" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=130654" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=130654" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. JAMA Oncol 2019; 5:1325.</a></li><li><a class="nounderline abstract_t">Xicola RM, Li S, Rodriguez N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019; 56:838.</a></li><li><a class="nounderline abstract_t">Hansford S, Kaurah P, Li-Chang H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 2015; 1:23.</a></li><li><a class="nounderline abstract_t">van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361.</a></li><li><a class="nounderline abstract_t">Passi M, Gamble LA, Samaranayake SG, et al. Association of CDH1 Germline Variants and Colon Polyp Phenotypes in Patients with Hereditary Diffuse Gastric Cancer. Gastro Hep Adv 2023; 2:244.</a></li><li><a class="nounderline abstract_t">Stanich PP, Elgindi D, Stoffel E, et al. Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis. Am J Gastroenterol 2022; 117:1877.</a></li><li><a class="nounderline abstract_t">Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020; 21:e386.</a></li></ol></div><div id="topicVersionRevision">Topic 130654 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246251" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31296550" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26182300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979631" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36776716" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of CDH1 Germline Variants and Colon Polyp Phenotypes in Patients with Hereditary Diffuse Gastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36087100" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758476" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hereditary diffuse gastric cancer: updated clinical practice guidelines.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
